Trial Profile
Phase II study of celecoxib in HER-2/neu overexpressing metastatic breast cancer patients who have failed recombinant humanized anti-p 185 HER monoclonal antibody trastuzumab (Herceptin)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2007 New trial record.